BCDA vs. CHRO, GENE, ONVO, IKT, COEP, TVGN, SRNE, SCNI, CELZ, and NSTGQ
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Chromocell Therapeutics (CHRO), Genetic Technologies (GENE), Organovo (ONVO), Inhibikase Therapeutics (IKT), Coeptis Therapeutics (COEP), Tevogen Bio (TVGN), Sorrento Therapeutics (SRNE), Scinai Immunotherapeutics (SCNI), Creative Medical Technology (CELZ), and NanoString Technologies (NSTGQ). These companies are all part of the "biological products, except diagnostic" industry.
BioCardia (NASDAQ:BCDA) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.
In the previous week, BioCardia had 6 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 6 mentions for BioCardia and 0 mentions for Chromocell Therapeutics. BioCardia's average media sentiment score of 0.49 beat Chromocell Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the media.
Chromocell Therapeutics has a net margin of 0.00% compared to BioCardia's net margin of -2,208.76%. Chromocell Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.
20.6% of BioCardia shares are owned by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are owned by institutional investors. 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioCardia received 10 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.
BioCardia currently has a consensus price target of $4.00, suggesting a potential upside of 1,042.86%. Given BioCardia's higher probable upside, equities analysts plainly believe BioCardia is more favorable than Chromocell Therapeutics.
Chromocell Therapeutics has lower revenue, but higher earnings than BioCardia.
Summary
BioCardia beats Chromocell Therapeutics on 7 of the 11 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
